Black Rock Inc. Prometheus Biosciences, Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$103.46 - $126.29 $815,885 - $995,922	-7,886 Reduced 0.28%	2,799,818 $300 Million
Q4 2022 Feb 13, 2023	BUY	$36.06 - $117.21 $24.3 Million - $78.9 Million	673,432 Added 31.55%	2,807,704 $309 Million
Q3 2022 Nov 14, 2022	BUY	$28.17 - $59.01 $8.99 Million - $18.8 Million	319,310 Added 17.59%	2,134,272 $126 Million
Q2 2022 Aug 12, 2022	SELL	$22.39 - $38.94 $7.7 Million - $13.4 Million	-343,989 Reduced 15.93%	1,814,962 $51.2 Million
Q1 2022 May 12, 2022	SELL	$30.13 - $50.0 $54,776 - $90,900	-1,818 Reduced 0.08%	2,158,951 $81.5 Million
Q4 2021 Feb 10, 2022	BUY	$22.28 - $39.54 $27.2 Million - $48.3 Million	1,220,649 Added 129.84%	2,160,769 $85.4 Million
Q3 2021 Nov 09, 2021	BUY	$20.89 - $26.96 $19,678 - $25,396	942 Added 0.1%	940,120 $22.3 Million
Q2 2021 Aug 11, 2021	BUY	$16.8 - $29.65 $15.8 Million - $27.8 Million	939,178 New	939,178 $23.1 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.